Treatment with dupilumab may help patients with uncontrolled, moderate to severe asthma achieve “clinical asthma remission.”
Patients with atopy may experience less severe outcomes when diagnosed with COVID-19.
Weekly dupilumab improved disease-specific health-related quality of life and symptom burden in adolescent and adult patients with eosinophilic esophagitis.
Patients with severe CRSwNP have worse health-related quality of life burden than the general population despite having a history of systemic corticosteroid and surgery, or comorbid asthma or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease.
Researchers have developed a scoring system that assesses lower respiratory and extra-respiratory symptoms and better monitors aspirin-induced reaction severity in patients with aspirin-exacerbated respiratory disease.
Mepolizumab reduces disease symptoms in patients with chronic rhinosinusitis with nasal polyps, according to the results of a randomized, double-blind, multicenter study.
Patients with asthma who depend on oral corticosteroids (OCS) may be able to reduce the dependence or eliminate the use of OCS altogether with benralizumab.
The use of CREON2000A UV air irradiation system technology reduced asthma severity in children with mild to moderate asthma.
Berotralstat may reduce the use of on-demand medications in patients with hereditary angioedema (HAE) who were previously treated with prophylactic therapies.
Black/African American and Hispanic individuals compared with White/Caucasian individuals were found to be highly underrepresented in food allergy immunotherapy trials.